Search Immortality Topics:

Page 21234..1020..»

Anatomy of a crisis: The North Korea threat – POLITICO.eu

Posted: August 16, 2017 at 5:50 pm

July 28, 2017

North Korea tests a ballistic missile experts say could reach the continental United States.

August 5, 2017

The United Nations Security Council unanimously passes sanctions on North Korean exports in response to its missile tests.

The United Nations Security Council just voted 15-0 to sanction North Korea. China and Russia voted with us. Very big financial impact!

Donald J. Trump (@realDonaldTrump) August 5, 2017

August 8, 2017

Trump promises Fire and Fury will meet North Korean threats.

North Korea best not make any more threats to the United States. They will be met with fire and fury like the world has never seen.

August 10, 2017

General Kim Rak Gyom, head of North Koreas strategic missile forces, outlined a plan to fire missiles into the waters around Guam and derided President Trump.

Sound dialogue is not possible with such a guy bereft of reason and only absolute force can work on him.

August 11, 2017

President Trump warns U.S. military is prepared to respond to any North Korean attack.

Military solutions are now fully in place,locked and loaded,should North Korea act unwisely. Hopefully Kim Jong Un will find another path!

Donald J. Trump (@realDonaldTrump) August 11, 2017

August 11, 2017

Guams Joint Information Center releases a fact sheet preparing for an imminent missile threat.

For years, North Korea has had the ability to launch short-range missiles at targets up to 800 miles away. But this year, North Korea successfully tested intermediate-range and intercontinental ballistic missiles. Experts now think the country is capable of hitting targets more than 7,000 miles away, which includes cities in the continental United States.

North Koreas nuclear program has grown under Kim Jong Un, while missile ranges have considerably expanded. Kim conducted 24 missile tests in 2016 and 14 tests already in 2017.

Only 2,100 miles southeast of North Korea, Guam is a strategic target because of its two American military bases Andersen Air Force Base and Naval Base Guam. There are 3,831 U.S. military personnel stationed there in addition to several B-1 bombers and fighter jets.

Read the rest here:
Anatomy of a crisis: The North Korea threat – POLITICO.eu

Recommendation and review posted by Guinevere Smith

OECS highlights outstanding Grenadian making strides in biotechnology – St. Lucia News Online

Posted: August 16, 2017 at 5:50 pm

Dr. Dwayne E. Carter,Post Doctoral Researcher, Tissue Applications.

(PRESS RELEASE) A national of Grenada, Dr. Dwayne E. Carter received his formation in the sciences at the Grenada Boys Secondary School and the T. A. Marryshow Community College in his hometown of Saint Georges.

Dwayne would later migrate to the United States to further pursue his passion for medicine and his curiosity to better understand and cure diseases that plague the human race. After years of study, Dwayne completed his doctoral training in cell biology at the University of Texas Medical Branch where he primarily focused on acute alcohol induced liver injury.

In 2016, he joined ORGANOVO Holdings Inc. as a post-doctoral researcher in liver tissue bioengineering with a focus on modeling progressive liver diseases. Throughout his graduate training, Dwayne received numerous awards for meritorious research from national scientific meetings and has two publications in peer reviewed journals.

When asked about the advice that he would give to young persons in the sub region that may be interested in an investigative science career, Dwayne said: This is a long road but the journey is worth it. A tip is to always make goals for yourself and plan strategic ways to achieve those goals.

Also be prepared to fight for what you want! Very few things are handed to you in this world, so brace yourself for times of adversity because you will inevitably be faced with challenges and the way you deal with them determines your success or failure.

At this stage in my life I consider myself a fighter, I look forward to the challenges because Ive learnt that they bring forward my best, he said.

Dr. Carter will be delivering a presentation on Modeling Human Biology, Drug Response and Progressive Liver Disease Using 3D Bioprinted Human Liver Tissue at the Committee Lecture Hall at TSRI, La Jolla, California at 7:00pm today, August 16, 2017.

ABOUT THE PRESENTATION:

Nonalcoholic fatty liver disease (NAFLD) is a chronic condition that originates as lipid accumulation within hepatocytes (steatosis) and progresses into nonalcoholic steatohepatitis (NASH), characterised by lipid accumulation, inflammation, oxidative stress, and fibrosis. NAFLD is now recognised as the most common cause of chronic liver disease, with a prevalence of 25% worldwide, and is projected to become the leading indication for liver transplant by 2025.

Despite decades of research in rodents and 2D cell cultures, the mechanisms of NAFLD progression, therapeutic approaches and non-invasive diagnostics are still resoundingly absent. Thus, there is a significant need for a more predictive human multicellular 3D in vitro model to study the progression of steatosis into NASH.

Using immune competent ExVive Human Liver Tissue, an in vitro 3D bioprinted liver, Dr. Carter will show preliminary data where the key features of NASH such as steatosis, fibrosis and inflammation will be modeled via nutrient overload followed by inflammatory stimulation using prototypical inducers.

ABOUT THE OECS FEATURE SERIES:

The OECS Feature Series is an initiative that seeks to feature the accomplishments of consummate professionals from OECS Member States making strides within the region and in the Diaspora.

The project highlights one outstanding OECS national per month and aims to inspire the regions youth to think big and open their minds to extraordinary possibilities through the success stories of their OECS peers.

Criteria for nominations include: being a national of an OECS Member State; possessing an academic distinction of the highest order; scientific invention; high political accomplishment (regionally and in the Diaspora); and extraordinary community or national service achieved (regionally and in the Diaspora).

This article was posted in its entirety as received by stlucianewsonline.com.This media house does not correct any spelling or grammatical error within press releases and commentaries.The views expressed therein are not necessarily those of stlucianewsonline.com, its sponsors or advertisers.

Originally posted here:
OECS highlights outstanding Grenadian making strides in biotechnology – St. Lucia News Online

Recommendation and review posted by Guinevere Smith

Oxford Immunotec value drops after public offering – European Biotechnology

Posted: August 16, 2017 at 5:50 pm

UK-headquartered immunodiagnostics specialist Oxford Immunotec Global plc’s share value slipped by $1.31 to $16.02 after the company raised US-$40.125m on Monday in an public offering of 2.5 million ordinary shares at Nasdaq underwritten by BTIG LLC.

Oxford Immunotec said it will use the proceeds from the offering for working capital and general corporate purposes. The companys immunodiagnostic T-SPOT platform is measures immune cell responses at a single cell level and thus detects immune responses of T cells and cells of the innate immune system more sensitive than ELISA assays. According to the British company, its assays can detect an individual reacting cell in a population of 250,000 white blood cells.

Oxford Immunotecs first product, the T-SPOT.TB test, has been approved for sale in over 50 countries, including the US, the EU, Japan and China. The companys second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. The company currently is seeking FDA approval for its third product line, a screening test for Babesia in donated blood. Additionally Oxford Immunotec has several assays, such T-SPOT.CMV test and the T-SPOT.PRT under development.

Excerpt from:
Oxford Immunotec value drops after public offering – European Biotechnology

Recommendation and review posted by Guinevere Smith

Mangaluru: Striding forward in biotechnology – Yenepoya University awarded grant – Daijiworld.com

Posted: August 16, 2017 at 5:50 pm

Daijiworld Media Network Mangaluru (ANK)

Addressing media persons here on Wednesday August 16 he said, “MultiOMICS is a highly interdisciplinary subject which includes genomics, proteomics, metabolomics and proteogenomics. Yenepoya University is one among the 18 institutions in Karnataka selected for the programme. This is the only centre to offer BiSEP course in multiOMICS technology, as it houses state-of-the-art facilities and scientists who are specialists in cutting edge technologies to undertake such training programmes.

“Centre for systems biology and molecular medicine has an advanced mass spectrometry facility with the latest generation high resolution mass spectrometer, one of the only three available in India. The trainers of this course have extensive experience in the field of OMICS technology and over the years have conducted several workshops and training sessions for researchers. Students trained by the course co-coordinators are placed in biotechnology companies such as Syngene, Thermo, Lupin and Pierian Dx and renowned institutes in countries including USA, Australia, Norway, Isreal and Singapore, he added.

Dr Arun, Dr Keshav Datta and others were present.

Original post:
Mangaluru: Striding forward in biotechnology – Yenepoya University awarded grant – Daijiworld.com

Recommendation and review posted by Fredricko

Tracking Trends in Biotechnology – Markets Insider

Posted: August 16, 2017 at 5:50 pm

LAS VEGAS, August 15, 2017 /PRNewswire/ —

The healthcare sector is made up of several different industries, from pharmaceuticals to biotechnology to health insurance. Making predictions in this sector can be difficult as there are many variables working with and against each other at one time. It’s important to track both negative and positive trends in healthcare companies. Investors who track these trends, make the best out of their predictions.

Certain trends in healthcare an investor should track include: the aging population and their healthcare needs, personalized medicine, the global reach of certain diseases, obesity and diabetes epidemic, and of course, technological advances. All of these trends mean different things in healthcare stock. Biotech companies are working tirelessly to address specific trends in human health, identifying the companies who are working with healthcare trends is key.

Some such companies include: Endonovo Therapeutics, Inc. (OTC: ENDV), Juno Therapeutics, Inc. (NASDAQ: JUNO), Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), Genocea Biosciences, Inc. (NASDAQ: GNCA), and TherapeuticsMD, Inc. (NYSE: TXMD)

Endonovo Therapeutics, Inc. (OTCQB: ENDV)

Market Cap: $7.3M, current share price: .028

ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They are addressing several healthcare trends with their electroceutical platform, which is a non-invasive, non-implantable device for treating inflammatory conditions in vital organs. Through the innovative research at ENDV, they are addressing most of the major healthcare trends by developing therapies to treat the aging population and addressing obesity and the complications that it entails, such as peripheral artery disease, heart disease, diabetic kidney disease and non-alcoholic steatohepatitis (NASH). Additionally, ENDV is working to address global diseases, kidney disease, and organ failure.

Tracking ENDV and their work in research and development (R&D) is something anyone interested in healthcare or biotech stocks should do. As their research correlates and ebbs and flows with healthcare trends. Some highlights regarding ENDV’s R&D are below:

As ENDV moves forward and inches closer to announcing the results of their pre-clinical studies across their diverse technology platform, you’ll want to stay up-to-date with their successes.

Other healthcare and biotech companies to review

Juno Therapeutics, Inc. (JUNO)

Market Cap: $3.021B, current share price: 28.30

JUNO, a clinical-stage cell immunotherapy company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer, has achieved recent milestones with its collaboration with Editas Medicine, Inc. (EDIT) This collaboration began over two years ago, the two companies are pursuing three research programs that aim to combine Editas Medicine’s genome editing platform with Juno’s CAR and TCR technologies.

Their most recent achievement relates to the improvement in the ability of T cells to overcome the tumor microenvironment. Editas Medicine will receive $2.5 million for achieving this milestone.

Eleven Biotherapeutics, Inc. (EBIO)

Market Cap: $35.2M, current share price: 1.425

EBIO is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform. They announced this week that they’ll be hosting a live conference call to announce their Q2 financial results.

This is scheduled for 8:00 a.m. ET on Monday, August 14, 2017. To access the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) at least five minutes prior to the start time and refer to conference ID 63779857.

Genocea Biosciences, Inc. (GNCA)

Market Cap: $112.74M, current share price: 3.955

Similarly to JUNO and EDITS collaboration on moving research forward regarding T cells, GNCA’s lead candidate is a novel T cell-directed immunotherapy for genital herpes. Today marks a horrible day for GNCA’s performance on the stock market. GNCA’s shares closed down 7.42% on Thursday with a little over 600,000 shares traded. The company reported second quarter financial results this week and reported a loss of $15.4 million.

On a per share basis, this was a loss of 54 cents while Wall Street was only expecting a loss of 46 cents. Keep a lookout for this stock as its performance is expected to continue to plummet.

TherapeuticsMD, Inc. (TXMD)

Market Cap: $1.15B, current share price: 5.630

TXMD, an innovative women’s healthcare company, just received a formal General Advice Letter from the FDA stating that an initial review has been completed and requesting that the Company submit the additional endometrial safety information to the NDA for TX-004HR on or before September 18, 2017.

This is great news for TXMD although they’ve been ranked negatively in the HealthCare Sector. Investors who seek profit from falling equity prices should target TXMD. Short interest is extremely high for TXMD with more than 20% of shares on loan.

Microcap Speculators

Email: rel=”nofollow”>[email protected]

Phone: +1-702-720-6310

Website: http://microcapspeculators.com/

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link:http://microcapspeculators.com/disclaimer/

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact

FN Media Group, LLC

rel=”nofollow”>[email protected]

+1-(954)-345-0611

Continued here:
Tracking Trends in Biotechnology – Markets Insider

Recommendation and review posted by Fredricko

Puma Biotechnology Inc (PBYI) Shares Needle Moving 1.99% – Morgan Research

Posted: August 16, 2017 at 5:50 pm

Shares ofPuma Biotechnology Inc (PBYI) is moving on volatility today1.99% or 1.60 from the open.TheNASDAQ listed companysaw a recent bid of82.15 on627761 volume.

There are various factors to examine when looking at what spurs growth in the stock market. Many investors will monitor macro-economic factors that influence the price of shares. Some of these factors include the overall condition of the economy and market sentiment. Following the macro factors, investors may employ a top down approach when viewing the equity markets. This may include starting with a sector poised for growth and filtering down to specific stock that meet the investors criteria. Another way to approach the stock market is to view the micro-economic factors that influence stocks. This may include studying company profits, news, and the competence of overall management. Investors will often try to piece together all the different information available in order to select stocks that will have a positive impact on the long-term strength of the portfolio.

Digging deeping into the Puma Biotechnology Inc (PBYI) s technical indicators, we note that the Williams Percent Range or 14 day Williams %R currently sits at -59.16. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

Puma Biotechnology Inc (PBYI) currently has a 14-day Commodity Channel Index (CCI) of -34.06. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Currently, the 14-day ADX for Puma Biotechnology Inc (PBYI) is sitting at 40.95. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, the 14-day RSI for Puma Biotechnology Incis currently at 45.59, the 7-day stands at 47.11, and the 3-day is sitting at 67.10.

Shares ofTiffany & Co (TIF) aremoving on volatility today1.35% or 1.19 from the open.TheNYSE listed companysaw a recent bid of 89.30 and626967shares have traded hands in the session.

Stock analysis typically falls under the two main categories of fundamental and technical. Fundamental analysis involves diving into company financials. Fundamental analysts study how the company is performing in order to determine whether or not the stock is ready to run. With this type of analysis, investors will be looking at balance sheet strength and gauging how much money the company is giving back to shareholders. After crunching all the numbers, investors can use the information to calculate ratios to help determine if the company is properly valued and worth adding to the portfolio. Technical analysis relies on charting historical stock prices in order to define trends and patterns. The buying and selling of stocks using only technical analysis typically removes any concern for how the company is fairing or even what it actually does. Some indicators that technical analysts use can be super simple and others can be highly complex. Many investors will attempt to study both technicals and fundamentals with the goal of gaining greater knowledge of where the stock has been, and where it might be going.

Taking a deeper look into the technical levels ofTiffany & Co (TIF), we can see thatthe Williams Percent Range or 14 day Williams %R currently sits at -75.72. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

Tiffany & Co (TIF) currently has a 14-day Commodity Channel Index (CCI) of -111.90. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, Tiffany & Cos 14-day RSI is currently at 39.93, the 7-day stands at 36.60, and the 3-day is sitting at 42.24.

Currently, the 14-day ADX for Tiffany & Co (TIF) is sitting at 20.66. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

See the article here:
Puma Biotechnology Inc (PBYI) Shares Needle Moving 1.99% – Morgan Research

Recommendation and review posted by Fredricko


Page 21234..1020..»